Quantcast

Latest antibodies Stories

2014-02-21 08:26:00

DALLAS, February 21, 2014 /PRNewswire/ -- RnRMarketResearch.com offers cancer monoclonal antibodies market (mABs) research reports covering pipeline analysis as well as monoclonal antibodies market forecasts in breast cancer, colorectal cancer as well as gastric and esophageal cancers to 2019. There are currently three monoclonal Antibody (mAb) treatments approved for metastatic colorectal cancer with the purpose of extending the patient's lifespan; Avastin, Erbitux and...

Studies Of Cow Antibodies Help Scientists Understand How Our Own Bodies Work
2014-02-19 12:20:46

American Institute of Physics Understanding how antibodies work is important for designing new vaccines to fight infectious diseases and certain types of cancer and for treating disorders of the immune system in animals and humans. In research to be presented at the 58th Annual Biophysical Society Meeting, taking place in San Francisco from Feb. 15-19, Dr. Damian Ekiert, who is now at the University of California, San Francisco, will describe research he conducted as part of a team of...

2014-02-18 08:32:37

BURNABY, BC, Feb. 18, 2014 /PRNewswire/ - Innovative Targeting Solutions Inc. (ITS) a pioneer in novel protein engineering technologies, today announced the successful application of the company's proprietary affinity maturation technology for the purposes of generating antibodies with pM affinities. These first in class antibodies are unique in that all mutations are specifically targeted to CDRs, unlike error prone PCR, somatic hypermutation or other traditional mutagenesis...

2014-02-18 08:30:40

LONDON, Feb. 18, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical IndustryA comparative analysis and assessment of TCR technologies, pipelines and companies from an industry perspectiveTherapeutic monoclonal antibodies have become an increasingly successful treatment modality with sales of US$ 65 bln in the year 2012 and with an...

2014-02-11 10:57:21

In 2011, biologists at the California Institute of Technology (Caltech) demonstrated a highly effective method for delivering HIV-fighting antibodies to mice—a treatment that protected the mice from infection by a laboratory strain of HIV delivered intravenously. Now the researchers, led by Nobel Laureate David Baltimore, have shown that the same procedure is just as effective against a strain of HIV found in the real world, even when transmitted across mucosal surfaces. The findings,...

2014-02-07 12:39:53

A team led by scientists at The Scripps Research Institute (TSRI) has discovered an unusual bacterial protein that attaches to virtually any antibody and prevents it from binding to its target. Protein M, as it is called, probably helps some bacteria evade the immune response and establish long-term infections. If follow-up studies confirm Protein M's ability to defeat the antibody response, it is likely to become a target of new antibacterial therapies. The protein's unique ability to...

2014-02-06 23:24:53

MarketResearchReports.Biz announces addition of new report “Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth Description” to its database. Visit: http://www.marketresearchreports.biz/analysis/186872 Albany, NY (PRWEB) February 06, 2014 Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth Description Research...

2014-02-06 16:27:50

MONROVIA, Calif., Feb. 6, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that Bassil Dahiyat, Ph.D., Chief Executive Officer, will present at the 2014 Leerink Global Healthcare Conference on Thursday, February 13, 2014 at 2:15 p.m. EST at the Waldorf Astoria Hotel in New York, NY. A live audio...

2014-02-06 16:26:57

LA JOLLA, Calif., Feb. 6, 2014 /PRNewswire-USNewswire/ -- A team led by scientists at The Scripps Research Institute (TSRI) has discovered an unusual bacterial protein that attaches to virtually any antibody and prevents it from binding to its target. Protein M, as it is called, probably helps some bacteria evade the immune response and establish long-term infections. If follow-up studies confirm Protein M's ability to defeat the antibody response, it is likely to become a target of...

2014-02-05 12:29:15

The feat bolsters rational vaccine design approach that could also be applied to other challenging viruses including HIV and influenza LA JOLLA, Calif., Feb. 5, 2014 /PRNewswire-USNewswire/ -- Scientists at The Scripps Research Institute (TSRI) have invented a new method for designing artificial proteins, and have used it to make key ingredients for a candidate vaccine against a dangerous virus, respiratory syncytial virus (RSV), a significant cause of infant mortality. The virus has...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related